Immunoassay-based determination of in-solution binding kinetics

Patent metadata

Field	Value
Publication number	US-12416631-B2
Application number	US-202318523859-A
Country	US
Kind code	B2
Filing date	Nov 29, 2023
Priority date	Aug 8, 2012
Publication date	Sep 16, 2025
Grant date	Sep 16, 2025

Abstract

Herein is reported a method for the determination of the binding affinity of a binder and its ligand comprising the step of determining based on the result of an immunoassay the fraction of free binder in a sample comprising binder, ligand and binder-ligand-complexes for at least two different binder:ligand ratios in the sample, and if the determined fraction of free binder is not comparable for all used binder:ligand ratios then the binder:ligand ratio in the sample is lowered and the sample is re-analyzed by the same immunoassay, and calculating based on the fraction of free binder in the previous step the binding affinity for the binder to its ligand.

First claim

The invention claimed is:

1. A method for the determination of the binding affinity (K D value) of a drug to its target comprising the following steps:
(a)(i) determining the fraction of free drug in at least three samples with different drug:target ratios, each of which samples comprises drug, target and non-covalent drug-target complexes,
whereby in the at least three samples the amount of drug is kept constant and the amount of target is different in each sample, with the proviso that the sample comprises an excess of target concentration compared to drug concentration,

or
determining the free target fraction in at least three samples with different drug:target ratios,
whereby in the at least three samples the amount of target is kept constant and the amount of drug is different in each sample, with the proviso that the sample comprises an excess of drug concentration compared to target concentration, wherein said free drug fraction or said free target fraction is determined by an immunoassay;

(a)(ii) calculating based on the fraction of free drug or calculating based on the fraction of free target determined in the previous step the binding affinity of the drug to its target for each of said at least three samples, thereby generating at least three K D values, wherein for the calculation of the K D value the following equation is used: K D =[(free drug fraction)*(target concentration [nM])]/(1−free drug fraction); and
(b) determining whether the three K D values are comparable, wherein the K D values are comparable if the relative difference of the highest and lowest K D values is less than 100%, and wherein relative difference is calculated using the following formula: relative difference=[(highest value)−(lowest value)]/(arithmetic mean of the values);
whereby if the at least three K D values are comparable, the binding affinity is determined, and
whereby if the at least three K D values are not comparable, method steps (a) and (b) are repeated using samples in which either
i) the amount of target is reduced at a constant amount of the drug, or
ii) the amount of drug is reduced at a constant amount of the target, compared to the samples used in the previous determination.

2. The method according to claim 1 , wherein the sample comprises serum or plasma.

3. The method according to claim 1 , wherein the drug is an antibody and the target is the antigen that is specifically bound by the antibody.

4. The method according to claim 1 , wherein the target is immobilized on a solid phase.

5. The method according to claim 1 , whereby in the at least three samples the amount of drug is kept constant and the amount of target is different in each sample, with the proviso that the sample comprises excess of target concentration compared to drug concentration, and wherein the excess target concentration compared to drug concentration is at least 40 times.

6. The method according to claim 1 , whereby in the at least three samples the amount of target is kept constant and the amount of drug is different in each sample, with the proviso that the sample comprises excess of drug concentration compared to target concentration, and wherein the excess drug concentration compared to target concentration is at least 40 times.

Assignees

• Hoffmann La Roche

Inventors

• Dahl Uwe
• Jordan Gregor
• Staack Roland

Classifications

• G01N33/15

  Medicinal preparations {; Physical properties thereof, e.g. dissolubility} · CPC title

• G01N33/557 Primary

  using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction · CPC title